RU2011144088A - ПЕПТИДЫ С6orf167 И СОДЕРЖАЩИЕ ИХ ВАКЦИНЫ - Google Patents
ПЕПТИДЫ С6orf167 И СОДЕРЖАЩИЕ ИХ ВАКЦИНЫ Download PDFInfo
- Publication number
- RU2011144088A RU2011144088A RU2011144088/10A RU2011144088A RU2011144088A RU 2011144088 A RU2011144088 A RU 2011144088A RU 2011144088/10 A RU2011144088/10 A RU 2011144088/10A RU 2011144088 A RU2011144088 A RU 2011144088A RU 2011144088 A RU2011144088 A RU 2011144088A
- Authority
- RU
- Russia
- Prior art keywords
- group
- cancer
- peptide according
- amino acid
- peptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 35
- 101000977257 Homo sapiens Protein MMS22-like Proteins 0.000 title claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 7
- 102100023475 Protein MMS22-like Human genes 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 150000001413 amino acids Chemical group 0.000 claims abstract 14
- 229940024606 amino acid Drugs 0.000 claims abstract 10
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims abstract 9
- 239000000427 antigen Substances 0.000 claims abstract 8
- 108091007433 antigens Proteins 0.000 claims abstract 8
- 102000036639 antigens Human genes 0.000 claims abstract 8
- 239000012634 fragment Substances 0.000 claims abstract 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract 6
- 229930182817 methionine Natural products 0.000 claims abstract 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims abstract 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract 4
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims abstract 3
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims abstract 3
- 108010013476 HLA-A24 Antigen Proteins 0.000 claims abstract 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract 2
- 229960000310 isoleucine Drugs 0.000 claims abstract 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract 2
- 238000006467 substitution reaction Methods 0.000 claims abstract 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 13
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 108091033319 polynucleotide Proteins 0.000 claims 7
- 239000002157 polynucleotide Substances 0.000 claims 7
- 102000040430 polynucleotide Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 230000014509 gene expression Effects 0.000 claims 5
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 4
- 239000003153 chemical reaction reagent Substances 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 230000004071 biological effect Effects 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 108010075704 HLA-A Antigens Proteins 0.000 claims 1
- 102000011786 HLA-A Antigens Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000002151 Pleural effusion Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000032383 Soft tissue cancer Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000001808 exosome Anatomy 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- -1 saliva Substances 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21170009P | 2009-04-01 | 2009-04-01 | |
| US61/211,700 | 2009-04-01 | ||
| PCT/JP2010/002352 WO2010113495A1 (en) | 2009-04-01 | 2010-03-31 | C6orf167 peptides and vaccines containing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011144088A true RU2011144088A (ru) | 2013-05-10 |
Family
ID=42827803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011144088/10A RU2011144088A (ru) | 2009-04-01 | 2010-03-31 | ПЕПТИДЫ С6orf167 И СОДЕРЖАЩИЕ ИХ ВАКЦИНЫ |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20120128705A1 (enExample) |
| EP (1) | EP2414383A4 (enExample) |
| JP (1) | JP5728759B2 (enExample) |
| KR (1) | KR20120034605A (enExample) |
| CN (2) | CN102448980B (enExample) |
| AU (1) | AU2010231381A1 (enExample) |
| BR (1) | BRPI1013384A2 (enExample) |
| CA (1) | CA2757210A1 (enExample) |
| IL (1) | IL215268A0 (enExample) |
| MX (1) | MX2011010191A (enExample) |
| RU (1) | RU2011144088A (enExample) |
| SG (2) | SG2014011423A (enExample) |
| TW (1) | TW201100090A (enExample) |
| WO (1) | WO2010113495A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007013671A2 (en) | 2005-07-27 | 2007-02-01 | Oncotherapy Science, Inc. | Method of diagnosing esophageal cancer |
| CN102884190B (zh) | 2010-03-11 | 2016-03-23 | 肿瘤疗法科学股份有限公司 | Hjurp肽及包含它们的疫苗 |
| JP2013542711A (ja) * | 2010-08-19 | 2013-11-28 | オンコセラピー・サイエンス株式会社 | がんの治療および診断の標的遺伝子としてのＣ６ｏｒｆ１６７ |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1273499A (en) * | 1997-10-24 | 1999-05-17 | Human Genome Sciences, Inc. | 148 human secreted proteins |
| CN1351069A (zh) * | 2000-10-26 | 2002-05-29 | 上海博德基因开发有限公司 | 一种新的多肽——鼠的同ampa受体相互作用的蛋白grip12.54和编码这种多肽的多核苷酸 |
| US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| CN101139392B (zh) * | 2002-09-12 | 2012-12-26 | 肿瘤疗法科学股份有限公司 | Kdr肽和包括该肽的疫苗 |
| JP4628208B2 (ja) * | 2004-08-10 | 2011-02-09 | オンコセラピー・サイエンス株式会社 | Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン |
| DK2325306T3 (en) * | 2005-02-25 | 2014-03-03 | Oncotherapy Science Inc | Peptide vaccines against lung cancers expressing TTK, URLC10 or KOC1 polypeptide |
| WO2007013671A2 (en) * | 2005-07-27 | 2007-02-01 | Oncotherapy Science, Inc. | Method of diagnosing esophageal cancer |
| EP2295571A1 (en) * | 2005-07-27 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing small cell lung cancer |
| JP5409658B2 (ja) * | 2008-03-13 | 2014-02-05 | セレラ コーポレーション | 静脈血栓症に関連した遺伝子多型、その検出方法および使用 |
-
2010
- 2010-03-30 TW TW099109539A patent/TW201100090A/zh unknown
- 2010-03-31 CN CN201080024056.0A patent/CN102448980B/zh not_active Expired - Fee Related
- 2010-03-31 WO PCT/JP2010/002352 patent/WO2010113495A1/en not_active Ceased
- 2010-03-31 JP JP2011542381A patent/JP5728759B2/ja not_active Expired - Fee Related
- 2010-03-31 AU AU2010231381A patent/AU2010231381A1/en not_active Abandoned
- 2010-03-31 EP EP10758274.4A patent/EP2414383A4/en not_active Withdrawn
- 2010-03-31 BR BRPI1013384A patent/BRPI1013384A2/pt not_active IP Right Cessation
- 2010-03-31 SG SG2014011423A patent/SG2014011423A/en unknown
- 2010-03-31 CN CN201510111822.1A patent/CN104774260A/zh active Pending
- 2010-03-31 SG SG2011071370A patent/SG174998A1/en unknown
- 2010-03-31 CA CA2757210A patent/CA2757210A1/en not_active Abandoned
- 2010-03-31 KR KR1020117025871A patent/KR20120034605A/ko not_active Withdrawn
- 2010-03-31 RU RU2011144088/10A patent/RU2011144088A/ru unknown
- 2010-03-31 MX MX2011010191A patent/MX2011010191A/es active IP Right Grant
- 2010-03-31 US US13/260,900 patent/US20120128705A1/en not_active Abandoned
-
2011
- 2011-09-21 IL IL215268A patent/IL215268A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010113495A1 (en) | 2010-10-07 |
| SG174998A1 (en) | 2011-11-28 |
| EP2414383A4 (en) | 2013-07-31 |
| TW201100090A (en) | 2011-01-01 |
| EP2414383A1 (en) | 2012-02-08 |
| CN104774260A (zh) | 2015-07-15 |
| BRPI1013384A2 (pt) | 2016-03-29 |
| CA2757210A1 (en) | 2010-10-07 |
| US20120128705A1 (en) | 2012-05-24 |
| CN102448980A (zh) | 2012-05-09 |
| MX2011010191A (es) | 2011-11-29 |
| JP5728759B2 (ja) | 2015-06-03 |
| KR20120034605A (ko) | 2012-04-12 |
| AU2010231381A1 (en) | 2011-11-03 |
| CN102448980B (zh) | 2015-04-15 |
| JP2012522488A (ja) | 2012-09-27 |
| IL215268A0 (en) | 2011-11-30 |
| SG2014011423A (en) | 2014-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2464275C2 (ru) | Пептидные вакцины для раков, экспрессирующих опухолеспецифические антигены | |
| RU2016138428A (ru) | Пептиды neil3 и включающие их вакцины | |
| JP2010519176A5 (enExample) | ||
| RU2011138160A (ru) | Пептиды foxmi и вакцины, содержащие их | |
| ES2373055T3 (es) | Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno. | |
| RU2009141595A (ru) | Пептиды тем8 и содержащие их вакцины | |
| JP2012520659A5 (enExample) | ||
| SG183718A1 (en) | Cdh3 peptide and medicinal agent comprising the same | |
| TW202115102A (zh) | 來自gpc3之胜肽、使用此胜肽之用於治療或預防癌症之醫藥組成物、免疫誘導劑、及抗原呈現細胞之製造方法 | |
| JP2014533095A5 (enExample) | ||
| RU2012136464A (ru) | Модифицированные пептиды melk и содержащие их вакцины | |
| RU2014121502A (ru) | Пептиды торк и содержащие их вакцины | |
| RU2015113436A (ru) | Пептиды ube2t и содержащие их вакцины | |
| RU2011144088A (ru) | ПЕПТИДЫ С6orf167 И СОДЕРЖАЩИЕ ИХ ВАКЦИНЫ | |
| CN103694315B (zh) | Cdc45l肽及包含它的疫苗 | |
| RU2011150283A (ru) | Пептиды ттк и вакцины, их содержащие | |
| RU2018116851A (ru) | Пептид, полученный из foxm1, и включающая его вакцина | |
| RU2018108197A (ru) | Пептид, полученный из depdc1, и содержащая его вакцина | |
| KR20070050993A (ko) | Ｃ형 간염 바이러스 유래 펩티드 | |
| RU2011140168A (ru) | Пептиды vangl1 и содержащие их вакцины | |
| RU2011120447A (ru) | Эпитопные пептиды rab6kifl/kif20a и содержащие их вакцины | |
| RU2011130796A (ru) | Пептиды c1orf59 и содержащие их вакцины | |
| JP2012522488A5 (enExample) | ||
| JP2021043204A (ja) | 免疫に基づく療法のための、免疫原性ｍｈｃクラスｉｉペプチドの同定 | |
| RU2019126629A (ru) | Пептид, полученный из koc1, и содержащая его вакцина |